In the specialized field of biochemical research, the study of protein aggregates remains a cornerstone for under by DA Butterfield·2004·Cited by 347—Amyloid beta-peptide (1-42)has been shown to induce oxidative stress and neurotoxicityin vitro and in vivo.Read more standing neurodegenerative processes. Among the various compounds studied, Amyloidbeta 1-42oligomers (SPR-488) and fibrils (SPR-487) show a dose-dependent toxicity to primary rat cortical neurons, but not monomers (SPR-485).Read more beta peptide 1-42—commonly referred to as Aβ (1-42)—stands out as a primary subject of investigation. As someone who has followed the development of recombinant proteins and peptides for laboratory use, I have Amyloid β Peptide (42-1)(human) observed how crucial high-quality, standardized reagents are for reproducing experimental results.
Understanding the Entity: Beta Peptide 1-42
At its core, this molecule is a 42-amino acid peptide derived from the amyloid precursor protein (APP) through the action of specific secretase enzymes. It is a human form of the predominant amyloid β-peptide identified in various biological models. Researchers often distinguish this from other variants, such as the 1-40 sequence, noting that the extra two amino acids significantly influence its aggregation kinetics.
The Aβ (1-42) structure is a critical area of study, as it is a major component of amyloid plaques and cerebrovascular deposits. Because this peptide is the predominant amyloid β-peptide found in plaques associated with Alzheimer's disease, it serves as a vital tool in *in vitro* and *in vivo* models designed to study protein misfolding and cellular stress.
Research Insights and Experimental Observations
When analyzing the role of these peptides, it is important to note that they are central to the pathogenesis of Alzheimer's disease in many experimental frameworks. My experience with these products highlights the importance of the peptide's state—whether it is supplied as monomers, oligomers, or fibrils.
* Aggregation Dynamics: The peptide may serve as a catalyst for the aggregatio Amyloid beta (Aβ) peptides, particularly the 42-residue variant Aβ 1-42,are central to the pathogenesis of Alzheimer's disease. While fibrillar aggregates form Read more n and deposition of β-amyloid peptide, making the handling of the material essential.
* Oxidative Stress: Evidence suggests that this specific sequence has been shown to induce oxidative stress and neurotoxicity in controlled laboratory settings.
* Quality Control: High-quality recombinant peptide Beta-Amyloid 1-42 (often treated with HFIP to ensure a monomeric state) is preferred for consistency.
Key Considerations for Laboratory Use
If you are sourcing beta peptide 1-42, you will likely encounter various configurations, β-Amyloid peptide 1-42 (Aβ 1-42) including FAM-labeled versions or the inactive β-Amyloid Peptide (Aβ) 42-1 control. The 42-1 variant acts as a negative control, as it is the inactive form.
For those focusing on the molecular weight, the Aβ (1-42) peptide typically has an apparent molecular mass of approximately 4 kDa. Given that these are peptides of 36 Human Amyloid Beta 1-42 Oligomers (SPR-488) –43 amino acids, maintaining the correct storage temperature—usually -20°C—is non-negotiable to prevent premature aggregation.
Why Specification Matters
Whether you are using Anti-Abeta (1-42) for detection or conducting structural analysis, the β-sheet transition is a well-documented phenomenon. The 1-42 sequence is unique because it transitions from a helical structure to a β-sheet, which is often the precursor to the formation of insoluble fibrils.
Summary
The study of beta peptide 1-42 continues to provide Amyloid beta-peptide(1-42) contributes to the oxidative stress deep insights into protein chemistry. Because it plays a key role in the pathogenesis of Alzheimer models, the precision of the peptide, its purity levels (often >95% or >97%), and its physical state (monomeric vs. fibrillar) are the most significant variables for any researcher. By utilizing High quality recombinant Beta-Amyloid (1-42), HFIP-treated products, laboratories can better ensure that their beta 1-42 experiments remain consistent, reproducible, and scientifically robust.
*Note: This content is intended for research and educational purposes only. It does not constitute medical advice or guidance for human use.*